{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"5.5","value":"4.8"},{"groupId":"OG001","lowerLimit":"1.8","upperLimit":"5.5","value":"2.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Progression-free survival from start of treatment to the time of disease progression or death from any cause was estimated using the Kaplan-Meier method.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients with Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Adenoid Cystic Carcinoma"},{"description":"Patients with non Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Non Adenoid Cystic Carcinoma"}],"paramType":"MEDIAN","populationDescription":"There are two subtype cohorts, adenoid cystic carcinoma and non adenoid cystic carcinoma of malignant salivary gland tumors, with the same treatment. The two groups were analyzed separately and therefore no comparisons are made between the two groups.","reportingStatus":"POSTED","timeFrame":"up to 5 years","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"months"}